Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1988 Aug;27(1):1–6. doi: 10.1007/BF00205750

In vitro activation of tumoricidal properties in mouse macrophages using the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) incorporated in liposomes

Kiyoshi Morikawa 1,✉, Rajiv Nayar 2, Isaiah J Fidler 1
PMCID: PMC11038545  PMID: 3396025

Abstract

We investigated the ability of free or liposome-incorporated synthetic chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) to generate tumoricidal properties in mouse macrophages. As FMLP contains three hydrophobic amino acid residues, it can readily be incorporated into multilamellar vesicles (MLV) consisting of phosphatidylcholine (PC) and phosphatidylserine (PS). The incorporation of FMLP into MLV with a PC:PS ratio of 7:3 mol at FMLP concentrations of up to 10−4 M did not affect the phagocytosis of liposomes by mouse peritoneal macrophages. Studies with radioactive FMLP revealed that higher levels of FMLP can be delivered to macrophages by liposomes than in the free, nonencapsulated form. Treatment of mouse macrophages with liposome-encapsulated FMLP, but not with free FMLP, generated tumoricidal properties in the macrophages. The mechanism appears to involve an intracellular site since 100-fold concentrations of free FMLP or free N-acetyl-methionyl-leucyl-phenylalanine, the FMLP agonist, failed to competitively inhibit the macrophage's tumoricidal properties generated by liposome-encapsulated FMLP.

Keywords: Peptide, Cancer Research, Amino Acid Residue, Phosphatidylcholine, Phosphatidylserine

References

  • 1.Adams DO, Hamilton TA. The cell biology of macrophage activation. Ann Rev Immunol. 1984;2:283. doi: 10.1146/annurev.iy.02.040184.001435. [DOI] [PubMed] [Google Scholar]
  • 2.Alving CR. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther. 1983;22:407. doi: 10.1016/0163-7258(83)90010-4. [DOI] [PubMed] [Google Scholar]
  • 3.Chedid L, Caredili L, Audibert F. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothel Soc. 1979;26:631. [PubMed] [Google Scholar]
  • 4.Chirigos MA, Talmadge JE. Immunotherapeutic agents: Their role in cellular immunity and their therapeutic potential. Springer Semin Immunopathol. 1985;8:327. doi: 10.1007/BF01857388. [DOI] [PubMed] [Google Scholar]
  • 5.Deodhar SD, James K, Chiang T, Edinger M, Barna BP. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res. 1982;42:5084. [PubMed] [Google Scholar]
  • 6.Ellouz F, Adam A, Ciorbarou R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974;59:1317. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  • 7.Fidler IJ. Macrophages and metastasis: A biological approach to cancer therapy. Cancer Res. 1985;45:4714. [PubMed] [Google Scholar]
  • 8.Fidler IJ, Fogler WE. Activation of tumoricidal properties in macrophages by lymphokines encapsulated in liposomes. Lymphokine Res. 1982;1:73. [PubMed] [Google Scholar]
  • 9.Fidler IJ, Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol. 1982;5:161. doi: 10.1007/BF00199794. [DOI] [PubMed] [Google Scholar]
  • 10.Fidler IJ, Raz A, Fogler WE, Hoyer LC, Poste G. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Cancer Res. 1981;41:495. [PubMed] [Google Scholar]
  • 11.Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptides. Proc Natl Acad Sci USA. 1981;78:1680. doi: 10.1073/pnas.78.3.1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fidler IJ, Fogler WE, Kleinerman ES, Saiki I. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon encapsulated in liposomes. J Immunol. 1985;135:4289. [PubMed] [Google Scholar]
  • 13.Fogler WE, Fidler IJ. The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction. J Immunol. 1986;136:2311. [PubMed] [Google Scholar]
  • 14.Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol. 1979;97:587. [PMC free article] [PubMed] [Google Scholar]
  • 15.Holian A, Daniele RP. Release of oxygen products from lung macrophages by N-formyl peptides. J Appl Physiol. 1981;50:736. doi: 10.1152/jappl.1981.50.4.736. [DOI] [PubMed] [Google Scholar]
  • 16.Karnovsky ML, Lazdins JK. Biochemical criteria for activated macrophages. J Immunol. 1978;121:809. [PubMed] [Google Scholar]
  • 17.Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 1983;43:2010. [PubMed] [Google Scholar]
  • 18.Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Invest. 1983;72:304. doi: 10.1172/JCI110970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh E. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol. 1983;130:1500. [PubMed] [Google Scholar]
  • 20.Marasco WA, Phan S, Krutzch H, Showell HJ, Feltner DE, Nairn R, Becker EL, Ward PA. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli . J Biol Chem. 1984;259:5430. [PubMed] [Google Scholar]
  • 21.Nayar R, Fidler IJ. The systemic activation of macrophages by liposomes containing imunomodulators. Springer Semin Immunopathol. 1985;8:413. doi: 10.1007/BF01857394. [DOI] [PubMed] [Google Scholar]
  • 22.North RJ. The concept of the activated macrophage. J Immunol. 1978;121:806. [PMC free article] [PubMed] [Google Scholar]
  • 23.Phillips NC, Mora ML, Chedid L, Lefrancier P, Bernard JM. Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 1985;45:128. [PubMed] [Google Scholar]
  • 24.Raz A, Fogler WE, Fidler IJ. The effect of experimental conditions on the expression of in vitro mediated tumor cytotoxicity mediated by murine macrophages. Cancer Immunol Immunother. 1979;7:157. [Google Scholar]
  • 25.Rossman MD, Cassizzi AM, Daniele RP. Adherence and morphology of guinea pig alveolar macrophages: Effect of N-formyl methionyl peptides. Infect Immun. 1980;29:1185. doi: 10.1128/iai.29.3.1185-1189.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Saiki I, Fidler IJ. Synergistic activation by recombinant mouse gamma interferon and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol. 1985;135:684. [PubMed] [Google Scholar]
  • 27.Schroit AJ (1982) Synthesis and properties of a nonexchangeable radioiodinated phospholipid biochemistry 21:5323 [DOI] [PubMed]
  • 28.Shiffmann E, Corcoran BA, Wahl SM. N-Formylmethionyl peptides as chemoattractants for leukocytes. Proc Natl Acad Sci USA. 1975;72:1059. doi: 10.1073/pnas.72.3.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Shin HSR, Snyderman R, Friedman E, Mellors A, Meyer MD. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science. 1968;162:361. doi: 10.1126/science.162.3851.361. [DOI] [PubMed] [Google Scholar]
  • 30.Showell HJ, Freer RJ, Zigmond SH, Schiffmann E, Aswanikumar S, Corcoran BA, Becker EL. The structure activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal enzyme secretion for neutrophils. J Exp Med. 1976;143:1154. doi: 10.1084/jem.143.5.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Snyderman R, Fudman EJ. Demonstration of a chemotactic factor receptor on macrophages. J Immunol. 1980;124:2754. [PubMed] [Google Scholar]
  • 32.Snyderman R, Pike MC. Transductional mechanism of chemoattractant receptors on leukocytes. Ann Rev Immunol. 1984;2:257. doi: 10.1146/annurev.iy.02.040184.001353. [DOI] [PubMed] [Google Scholar]
  • 33.Snyderman R, Shin HSR, Phillips JK, Gewurz H, Mergenhagen SE. A neutrophil chemotactic factor derived from C5 upon interaction of guinea pig serum with endotoxin. J Immunol. 1969;103:413. [PubMed] [Google Scholar]
  • 34.Williams LT, Snyderman R, Pike MC, Lefkowitz RJ. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci USA. 1977;74:1204. doi: 10.1073/pnas.74.3.1204. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES